Johnson & Johnson (JNJ) Gains from Investment Securities (2020)
Johnson & Johnson (JNJ) posted Gains from Investment Securities of -$200.0 million for Q3 2020, up 80.0% sequentially from -$1.0 billion in Q2 2020.
Johnson & Johnson (JNJ) Gains from Investment Securities (2020) Analysis & Trends
Johnson & Johnson has reported Gains from Investment Securities for 1 years, with the latest figure at -$200.0 million in Q3 2020.
- Quarterly Gains from Investment Securities changed N/A year-over-year to -$200.0 million in Q3 2020, while the trailing twelve-month figure through Jul 2021 was -$200.0 million (up 89.91% YoY) and the FY2021 annual result came in at -$1.1 billion, changed N/A from the prior year.
- Gains from Investment Securities grew to -$200.0 million in Q3 2020 per JNJ's latest filing, from -$1.0 billion in the prior quarter.
- Over five years, Gains from Investment Securities peaked at -$200.0 million in Q3 2020 and troughed at -$1.0 billion in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 27, 2020 | -200.00 Mn |
| Sep 27, 2020 | -200.00 Mn |
| Jun 28, 2020 | -1.00 Bn |
| Jun 28, 2020 | -1.00 Bn |
| Mar 29, 2020 | -983.00 Mn |
| Mar 29, 2020 | -983.00 Mn |